Aurobindo Pharma has informed that a meeting of the Board of Directors of the Company will be held on May 30, 2016, to consider the Audited Financial Results of the Company for the year ended March 31, 2016 and will also consider the proposal of payment of Dividend, if any, for the year 2015-16. Further that the ‘Trading Window’ of the Company shall remain closed from May 20, 2016 to June 01, 2016, in view of consideration of the Audited Financial Results of the Company for the year ended March 31, 2016 by the Board at the Meeting to be held on May 30, 2016. During this period the Promoters I Directors / Officers / Employees / Connected Persons of the Company are not permitted to purchase, sale or other dealings in the shares of the Company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: